Anteris Technologies Global Corp
NASDAQ:AVR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Anteris Technologies Global Corp
NASDAQ:AVR
|
229.5m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
191.3B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.7B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Anteris Technologies Global Corp
Glance View
Anteris Technologies Global Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eagan, Minnesota and currently employs 138 full-time employees. The company went IPO on 2024-12-13. Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. The company is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Anteris Technologies Global Corp is -3 924.2%, which is below its 3-year median of -3 375.1%.
Over the last 10 months, Anteris Technologies Global Corp’s Net Margin has decreased from -2 822.5% to -3 924.2%. During this period, it reached a low of -3 924.2% on Oct 30, 2025 and a high of -2 822.5% on Dec 1, 2024.
